Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs

Aya Hefnawy; Maya Berg; Jean-Claude Dujardin; Geraldine De Muylder

doi:10.1016/j.pt.2016.11.003

Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs

Aya Hefnawy, Maya Berg, Jean-Claude Dujardin, Geraldine De Muylder

Molecular Parasitology

Research output: Contribution to journal › A1: Web of Science-article › peer-review

Abstract

New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.

Original language	English
Journal	Trends In Parasitology
Volume	33
Issue number	3
Pages (from-to)	162-174
Number of pages	13
ISSN	1471-4922
DOIs	https://doi.org/10.1016/j.pt.2016.11.003
Publication status	Published - 2017

Keywords

AQUAGLYCEROPORIN AQP1 GENE
ABC-TRANSPORTER MRPA
VISCERAL LEISHMANIASIS
ANTIMONY-RESISTANT
INTRACELLULAR AMASTIGOTES
DONOVANI PROMASTIGOTES
GLUCANTIME-RESISTANT
TREATMENT FAILURE
L. DONOVANI
MILTEFOSINE

Access to Document

10.1016/j.pt.2016.11.003

Cite this

@article{c892240a9a374b71818c1983025b1bf7,

title = "Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs",

abstract = "New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.",

keywords = "AQUAGLYCEROPORIN AQP1 GENE, ABC-TRANSPORTER MRPA, VISCERAL LEISHMANIASIS, ANTIMONY-RESISTANT, INTRACELLULAR AMASTIGOTES, DONOVANI PROMASTIGOTES, GLUCANTIME-RESISTANT, TREATMENT FAILURE, L. DONOVANI, MILTEFOSINE",

author = "Aya Hefnawy and Maya Berg and Jean-Claude Dujardin and {De Muylder}, Geraldine",

note = "NPP",

year = "2017",

doi = "10.1016/j.pt.2016.11.003",

language = "English",

volume = "33",

pages = "162--174",

journal = "Trends In Parasitology",

issn = "1471-4922",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs

AU - Hefnawy, Aya

AU - Berg, Maya

AU - Dujardin, Jean-Claude

AU - De Muylder, Geraldine

N1 - NPP

PY - 2017

Y1 - 2017

N2 - New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.

AB - New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.

KW - AQUAGLYCEROPORIN AQP1 GENE

KW - ABC-TRANSPORTER MRPA

KW - VISCERAL LEISHMANIASIS

KW - ANTIMONY-RESISTANT

KW - INTRACELLULAR AMASTIGOTES

KW - DONOVANI PROMASTIGOTES

KW - GLUCANTIME-RESISTANT

KW - TREATMENT FAILURE

KW - L. DONOVANI

KW - MILTEFOSINE

U2 - 10.1016/j.pt.2016.11.003

DO - 10.1016/j.pt.2016.11.003

M3 - A1: Web of Science-article

C2 - 27993477

SN - 1471-4922

VL - 33

SP - 162

EP - 174

JO - Trends In Parasitology

JF - Trends In Parasitology

IS - 3

ER -

Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs

Abstract

Keywords

Access to Document

Fingerprint

Cite this